Shenzhen Kangtai Biological Products Co Ltd (300601) - Total Liabilities
Based on the latest financial reports, Shenzhen Kangtai Biological Products Co Ltd (300601) has total liabilities worth CN¥4.52 Billion CNY (≈ $661.98 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 300601 cash flow metrics to assess how effectively this company generates cash.
Shenzhen Kangtai Biological Products Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Shenzhen Kangtai Biological Products Co liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Shenzhen Kangtai Biological Products Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Kangtai Biological Products Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Awinic Technology Co Ltd
SHG:688798
|
China | CN¥1.07 Billion |
|
DRDGOLD Limited
F:DUBA
|
Germany | €2.64 Billion |
|
Asahi India Glass Limited
NSE:ASAHIINDIA
|
India | Rs42.00 Billion |
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
Argentina | AR$2.29 Trillion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥1.16 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr2.00 Billion |
|
SOC.BIC UNS.ADR1/2/EO382
F:BIF0
|
Germany | €948.55 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Shenzhen Kangtai Biological Products Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Shenzhen Kangtai Biological Products Co .
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Kangtai Biological Products Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Kangtai Biological Products Co Ltd (2012–2024)
The table below shows the annual total liabilities of Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥4.90 Billion ≈ $717.42 Million |
-11.56% |
| 2023-12-31 | CN¥5.54 Billion ≈ $811.21 Million |
+15.47% |
| 2022-12-31 | CN¥4.80 Billion ≈ $702.54 Million |
-3.64% |
| 2021-12-31 | CN¥4.98 Billion ≈ $729.06 Million |
+134.89% |
| 2020-12-31 | CN¥2.12 Billion ≈ $310.38 Million |
+77.03% |
| 2019-12-31 | CN¥1.20 Billion ≈ $175.33 Million |
-20.32% |
| 2018-12-31 | CN¥1.50 Billion ≈ $220.03 Million |
+31.93% |
| 2017-12-31 | CN¥1.14 Billion ≈ $166.77 Million |
+31.62% |
| 2016-12-31 | CN¥865.90 Million ≈ $126.71 Million |
+26.09% |
| 2015-12-31 | CN¥686.71 Million ≈ $100.49 Million |
-9.44% |
| 2014-12-31 | CN¥758.25 Million ≈ $110.96 Million |
+3.20% |
| 2013-12-31 | CN¥734.74 Million ≈ $107.52 Million |
+4.14% |
| 2012-12-31 | CN¥705.50 Million ≈ $103.24 Million |
-- |
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. The company's marketed vaccines include 13-valent pneumococcal polysaccharide conjugate vaccine, varicella vaccine, freeze-dried, hepatitis B vaccine, inflammatory vaccine, 23-valent pneumococcal polysaccharide vaccine, DTAP/HIB combined vaccine, diphtheria, tetanu… Read more